Diltiazem
Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
---|---|---|---|
Calcium Channel Blockers | Diltiazem | 120-360mg PO Q24H (sustained release) | Administer Anytime During HD; Post HD if Hypotensive |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
---|---|---|---|---|---|---|---|
414 | <5 | 3-4.4 | No change | 75-81 | 2.1-4.5 | N/A | N/A |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- Diltiazem. In:Lexi-Drugs Online. Hudson (OH): Lexi-Comp, Inc; [updated 04/23/12; accessed 04/23/12].
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00343
- Inrig J. Antihypertensive agents in hemodialysis patients: a current perspective. Seminars in dialysis. 2010;23(3):290-7.